Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs.
Our marketed product portfolio includes: XYREM® (sodium oxybate), ERWINAZETM (asparaginase Erwinia chrysanthemi), PRIALT® (ziconotide) solution, intrathecal infusion, FAZACLO® (clozapine, USP) LD and HD , and VERSACLOZ™ (clozapine, USP) oral suspension.
The product information on XYREM, ERWINAZE, PRIALT, FAZACLO LD and HD and VERSACLOZ is intended only for residents of the United States. For more information, including complete prescribing information and boxed warnings, click on the product names above.
Please visit www.EUSAPharma.com for more information about our international division, EUSA Pharma, and our products marketed outside the U.S.
We plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our unique commercial expertise. As we evaluate additional acquisition and in-licensing opportunities, we work closely with healthcare professionals and patient advocates to identify significant treatment gaps where Jazz Pharmaceuticals’ unique approach to patient care and patient-focused products may be able to bring a new therapeutic option to the market where none existed previously.
Our core values define our corporate practices and demonstrate our commitment to improving patients’ lives.
We’ve built a patient-focused commercial team with the goal of creating a sophisticated and specialized organization to serve the needs of the patient.